(Q51483804)
Statements
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. (English)
1 reference
Julio Rosenstock
1 reference
Ronald Brazg
1 reference
Paula J Andryuk
1 reference
Kaifeng Lu
1 reference
Peter Stein
1 reference
Sitagliptin Study 019 Group
1 reference
1 October 2006
1 reference
28
1 reference
10
1 reference
1556-1568
1 reference